13669-57-3

Usage

Uses

Used in Agricultural Industry:
3-Bromo-6-hydroxy quinoline is used as a reagent for the preparation of analogs of quinolin-6-yloxyacetamide fungicides. These fungicides are essential in protecting crops from fungal infections, ensuring higher crop yields and better quality produce.

Upstream product

• 7101-95-3 3-bromo-6-nitroquinoline 
• 7101-96-4 3-bromo-quinolin-6-ylamine 
• 1022151-47-8 3-bromoquinolin-6-yl acetate 
• 24306-33-0 methyl quinolin-6-ylethanoate 
• 580-16-5 6-hydroxyquinoline 

Downstream Products

• 696612-04-1 3-chloro-6-hydroxyquinoline 
• 1236301-32-8 C₁₇H₁₁BrCl₂FNO 
• 1337882-50-4 6-(benzyloxy)-3-bromoquinoline 
• 1393352-90-3 (S)-1-(6-(benzyloxy)quinolin-3-yl)-N,N-dimethylpyrrolidin-3-amine 
• 1393352-93-6 N-((6-(benzyloxy)quinolin-3-yl)methyl)-N-ethylethanamine 
• 14036-96-5 3-bromo-6-methoxyquinoline 
• 889660-68-8 3-iodo-6-hydroxyquinoline 
• 808755-53-5 3-fluoroquinolin-6-ol 
• 132410-41-4 3-Bromo-7-(2-carboxy-3,6-dimethoxy-benzyl)-6-methoxy-2H-quinoline-1-carboxylic acid methyl ester 
• 1427474-57-4 4-(6-(benzyloxy)quinolin-3-yl)-3-methylmorpholine 
• 727650-61-5 3-aminoquinolin-6-ol 
• 1427474-53-0 N-benzyl-6-(benzyloxy)quinolin-3-amine 
• 1427474-50-7 6-(benzyloxy)-N-(2-(tert-butyldimethylsilyloxy)ethyl)quinolin-3-amine 
• 1427473-97-9 6-(benzyloxy)-3-(4-methyl-1,4-diazepan-1-yl)quinoline 

Relevant academic research and scientific papers

Discovery of Inhibitors of the Lipopolysaccharide Transporter MsbA: From a Screening Hit to Potent Wild-Type Gram-Negative Activity

The dramatic increase in the prevalence of multi-drug resistant Gram-negative bacterial infections and the simultaneous lack of new classes of antibiotics is projected to result in approximately 10 million deaths per year by 2050. We report on efforts to target the Gram-negative ATP-binding cassette (ABC) transporter MsbA, an essential inner membrane protein that transports lipopolysaccharide from the inner leaflet to the periplasmic face of the inner membrane. We demonstrate the improvement of a high throughput screening hit into compounds with on-target single digit micromolar (μM) minimum inhibitory concentrations against wild-type uropathogenic Escherichia coli, Klebsiella pneumoniae, and Enterobacter cloacae. A 2.98 ? resolution X-ray crystal structure of MsbA complexed with an inhibitor revealed a novel mechanism for inhibition of an ABC transporter. The identification of a fully encapsulated membrane binding site in Gram-negative bacteria led to unique physicochemical property requirements for wild-type activity.

2'-(QUINOLIN-3-YL)-5',6'-DIHYDROSPIRO[AZETIDINE-3,4'-PYRROLO[1,2-B]PYRAZOLE]-1-CARBOXYLATE DERIVATIVES AND RELATED COMPOUNDS AS MAP4K1 (HPK1) INHIBITORS FOR THE TREATMENT OF CANCER

The present invention relates to Map4K1 inhibitors of formula (I), to pharmaceutical compositions and combinations comprising the compounds according to the invention, and to the prophylactic and therapeutic use of the inventive compounds, respectively to the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular for neoplastic disorders, respectively cancer or conditions with dysregulated immune responses or other disorders associated with aberrant MAP4K1 signaling, as a sole agent or in combination with other active ingredients. The present invention further relates to the use, respectively to the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of protein inhibitors in benign hyperplasias, atherosclerotic disorders, sepsis, autoimmune disorders, vascular disorders, viral infections, in neurodegenerative disorders, in inflammatory disorders, in atherosclerotic disorders and in male fertility control.

2,2,3-Tribromopropanal as a versatile reagent in the skraup-type synthesis of 3-bromoquinolin-6-ols

2,2,3-Tribromopropanal, a reagent which almost became forgotten in the chemical literature after its first application in the 1950s, is used for the one-step transformation of diversely substituted 4-nitro- and 4-methoxyanilines into 3-bromo-6-nitroquinolines and 3-bromo-6-methoxyquinolines. These intermediates are then converted, in one further step, into 3-bromoquinolin-6- ols, which may carry additional substituents at positions 7 and 8. Georg Thieme Verlag Stuttgart New York.

6 - SUBSTITUTED 3 - (QUINOLIN- 6 - YLTHIO) - [1,2,4] TRIAZOLO [4, 3 -A] PYRADINES AS TYROSINE KINASE

The invention relates to compounds of formula (I) and salts thereof: Formula (I) wherein the substituents are as defined in the specification; a compound of formula (I) for use in the treatment of the human or animal body, in particular with regard to c-Met tyrosine kinase mediated diseases or conditions; the use of a compound of formula (I) for manufacturing a medicament for the treatment of such diseases; pharmaceutical compositions comprising a compound of the formula (I), optionally in the presence of a combination partner, and processes for the preparation of a compound of formula (I).

TRIAZOLOPYRIDINE COMPOUNDS

The invention relates to compounds of formula (I) and salts thereof: wherein the substituents are as defined in the specification; a compound of formula (I) for use in the treatment of the human or animal body, in particular with regard to c-Met tyrosine kinase mediated diseases or conditions; the use of a compound o f formula (I) for manufacturing a medicament for the treatment of such diseases; pharmaceutical compositions comprising a compound of the formula (I), optionally in the presence of a combination partner, and processes for the preparation of a compound of formula (I)

[1,2,4] TRIAZOLO [4,3-B] PYRIDAZINE COMPOUNDS AS INHIBITORS OF THE C-MET TYROSINE KINASE

The invention relates to compounds of formula (I) and salts thereof: wherein the substituents are as defined in the specification; a compound of formula (I) for use in the treatment of the human or animal body, in particular with regard to c-Met tyrosine kinase mediated diseases or conditions; the use of a compound of formula (I) for manufacturing a medicament for the treatment of such diseases; pharmaceutical compositions comprising a compound of the formula (I), optionally in the presence of a combination partner, and processes for the preparation of a compound of formula (I).

[1, 2, 4] TRIAZOLO [4, 3 -B] PYRIDAZINE COMPOUNDS AS INHIBITORS OF THE C-MET TYROSINE KINASE

The invention relates to compounds of formula (I) and salts thereof: wherein the substituents are as defined in the specification; a compound of formula (I) for use in the treatment of the human or animal body, in particular with regard to c-Met tyrosine kinase mediated diseases or conditions; the use of a compound of formula (I) for manufacturing a medicament for the treatment of such diseases; pharmaceutical compositions comprising a compound of the formula (I), optionally in the presence of a combination partner, and processes for the preparation of a compound of formula (I).

QUINOLIN-, ISOQUINOLIN-, AND QUINAZOLIN-OXYALKYLAMIDES AND THEIR USE AS FUNGICIDES

Fungicidal compounds of the general formula (1) wherein one of X and Y is N or N-oxide and the other is CR or both of X and Y are N.